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Abstract
Background: The exact risk of developing QTc-prolongation when using a combination of QTc-prolonging drugs is
still unknown, making it difficult to interpret these QT drug-drug interactions (QT-DDIs). A tool to identify high-risk
patients is needed to support healthcare providers in handling automatically generated alerts in clinical practice.
The main aim of this study was to develop and validate a tool to assess the risk of QT-DDIs in clinical practice.
Methods: A model was developed based on risk factors associated with QTc-prolongation determined in a
prospective study on QT-DDIs in a university medical center inthe Netherlands. The main outcome measure was
QTc-prolongation defined as a QTc interval > 450 ms for males and > 470 ms for females. Risk points were assigned
to risk factors based on their odds ratios. Additional risk factors were added based on a literature review. The ability
of the model to predict QTc-prolongation was validated in an independent dataset obtained from a general
teaching hospital against QTc-prolongation as measured by an ECG as the gold standard. Sensitivities, specificities,
false omission rates, accuracy and Youden’s index were calculated.
Results: The model included age, gender, cardiac comorbidities, hypertension, diabetes mellitus, renal function,
potassium levels, loop diuretics, and QTc-prolonging drugs as risk factors. Application of the model to the
independent dataset resulted in an area under the ROC-curve of 0.54 (95% CI 0.51–0.56) when QTc-prolongation
was defined as > 450/470 ms, and 0.59 (0.54–0.63) when QTc-prolongation was defined as > 500 ms. A cut-off value
of 6 led to a sensitivity of 76.6 and 83.9% and a specificity of 28.5 and 27.5% respectively.
Conclusions: A clinical decision support tool with fair performance characteristics was developed. Optimization of
this tool may aid in assessing the risk associated with QT-DDIs.
Trial registration: No trial registration, MEC-2015-368.
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Background
QTc-prolongation is known as a risk factor for develop-
ing ventricular arrhythmias such as Torsade de Pointes
(TdP), which may eventually lead to sudden cardiac
death. Therefore, a prolonged heart-rate corrected QT(c)
interval is used as electrocardiogram (ECG) marker for an
increased risk of TdP; and thus a prolonged QTc-interval
should be avoided in patient care as a part of risk
minimization [1–3].
QTc-prolongation is defined as a QTc-interval > 450
ms in males and > 470 ms in females according to the
European Medicine Agency guidelines [4, 5]. However,
arrhythmias are frequently associated with QTc-intervals
exceeding 500ms. [6–8] A prolonged QTc-interval often
represents a delayed ventricular repolarization. Roden et al.
introduced a theory where some physiological mechanisms
create a buffer to maintain normal ventricular repolariza-
tion, the so-called repolarization reserve. Several risk factors
and genetic predisposition can reduce this repolarization
reserve causing abnormalities in the ventricular repolariza-
tion [9, 10]. Consequently, multiple risk factors are fre-
quently present in case reports describing patients who
developed serious QTc-prolongation or TdP [11, 12].
Several drugs are also responsible for developing QTc-
prolongation known as drug-induced QTc-prolongation.
Currently, over 190 drugs are associated with QTc-
prolongation according to the CredibleMeds® QT drug
lists of the Arizona Center for Education and Research
on Therapeutics (AZCERT). AZCERT categorizes QTc-
prolonging drugs into three categories representing the
level of certainty on the risk of TdP. More than 50 drugs
are categorized as drugs with a known risk of TdP [13].
Many of these drugs such as antibiotics and antidepres-
sants are widely used in clinical practice. QTc-
prolonging drugs are not further classified with respect
to the extent of QTc-prolongation. Also, the exact risk
of developing QTc-prolongation when using a combin-
ation of QTc-prolonging drugs is unknown. For health-
care professionals, such as physicians and pharmacists, it
is difficult to decide whether or not it is safe to proceed
treating a patient with combinations of two or more
QTc-prolonging drugs, and in whom additional checks
of ECGs after treatment initiation are needed.
Other risk factors include hypokalemia, hypomagnes-
emia, heart diseases (i.e. ischemic heart diseases, heart fail-
ure, and arrhythmia such as atrial fibrillation), and renal
impairment. Also, demographic risk factors such as an
older age, female sex and genetic predisposition are asso-
ciated with QTc-prolongation [2, 12, 14–16]. However,
the impact of these risk factors on the extent of QTc-
prolongation is largely unknown, which makes it challen-
ging to identify patients at risk for QTc-prolongation.
In the Netherlands, QT-DDI alerts are generated by the
Computerized Physician Order Entry (CPOE) systems
when two or more QTc-prolonging drugs with a known
risk of TdP are combined. QT-DDI alerts are generated ac-
cording to the so-called ‘G-Standard’, a Dutch drug data-
base which supports the different processes in healthcare,
such as prescription, dispensing, ordering, reimbursement,
and decision support [17]. The current guidelines incorpo-
rated in the ‘G-Standard’ regarding QT-DDIs suggest to
substitute or remove one of the interacting agents or per-
form routine ECG monitoring. As a result, first-line treat-
ments are frequently not adhered to when one of the
interacting agents is substituted, especially in primary care
where ECG monitoring is often not feasible. In tertiary care,
low adherence to guidelines result in many overridden DDI
alerts by physicians [18]; and ECG monitoring is rarely per-
formed when QT-DDI alerts are overridden [19, 20]. With
the increasing number of QTc-prolonging drugs, QT-DDI
alerts will reduce the physician responsiveness to this par-
ticular type of alert, also known as alert fatigue. The use of
a smart algorithm which generates specific alerts will re-
duce alert fatigue in clinical practice.
Methods
The aim, design and setting
The aim of this study was to develop and validate a clin-
ical decision support tool to assess the risk of QT-DDIs
in clinical practice.
A prospective, observational study design was chosen
to identify potential risk factors of QTc-prolongation in
patients using two or more QTc-prolonging drugs with
a known risk of TdP as part of their usual care. This
study was performed in the Erasmus University Medical
Center Rotterdam, the Netherlands. An external valid-
ation was performed on retrospective data obtained from
the Spaarne Gasthuis, a general teaching hospital with
locations in Haarlem and Hoofddorp, the Netherlands.
Identification of potential risk factors and data collection
In the prospective study, patients (≥18 years) admitted to
the Erasmus University Medical Center from September
2015 to March 2016 using two or more QTc-prolonging
drugs with ‘a known risk of TdP’ [13] were included. A
standard twelve-lead resting ECG (paper speed 25mm
s− 1, amplitude 10mmmV− 1 and sampling rate 250 Hz)
was recorded using the Mortara® ELI-350 ECG device
(Milwaukee, Wisconsin, USA) at the estimated time of
peak concentration (Tmax) of the lastly added drug, or at
the longest Tmax in case both drugs were started at the
same time. Exclusion criteria included ECGs with a
QTc-interval > 700 ms or < 300ms, or with a ventricular
rate (VR) > 180 beats per minute (bpm) or < 40 bpm as
such ECGs do not allow reliable measurements of QTc-
intervals; however, these ECGs were not present in our
cohort. Patients with a congenital long QT syndrome, an
implantable cardioverter-defibrillator (ICD) or a
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pacemaker were excluded. Also, patients with a left or
right bundle branch block (LBBB/RBBB), atrial fibrilla-
tion or other ECG abnormalities due to cerebral path-
ology, ischemia or bigeminy were excluded as these
comorbidities interfere with the QTc-interval.
The following data were prospectively collected from
the electronic patient health record (Elpado, Rotterdam,
the Netherlands): general patient characteristics includ-
ing comorbidities and the medical condition at time of
the ECG recording as well as the dose of the interacting
drugs. The serum sodium (mmol L− 1), potassium (mmol
L− 1), magnesium (mmol L− 1), and calcium (mmol L− 1)
levels were collected within 5 days before or after the
ECG recording, collecting the measurement closest to
the ECG recording. Calcium levels were corrected for al-
bumin levels [21]. The estimated glomerular filtration
rate (eGFR, mL min− 1) using the Modification of Diet in
Renal Disease (MDRD) formula, creatinine (μmol L− 1),
aspartate transaminase (ASAT, U L− 1), alanine amino-
transferase (ALAT, U L− 1), and bilirubin (μmol L− 1)
were also obtained within 5 days before or after the ECG
recording. Concomitant medication data were collected
from the CPOE system Medicator (Computer Sciences
Corporation (CSC) Healthcare Group, Leiden, the
Netherlands) within 8 h prior to the ECG recording [22].
The QT-intervals were manually measured, preferably
from lead II, from the onset of the QRS-complex to the
end of the T-wave using the tangent method. The QT-
interval was adjusted for heart rate using the Bazett
(QTc = QT/√RR) and Fridericia (QTc =QT/3√RR)
formula [23, 24].
Statistical analysis
Data were analyzed using Statistical Package for Social
Science (SPSS, IBM SPSS Statistics version 21.0, Armonk,
NY, United States). The QTc-interval was dichotomized
as either prolonged or not prolonged (QTc > 450ms for
males and QTc > 470ms for females) [8]. Univariate logis-
tic regression analysis was performed to determine poten-
tial risk factors, due to small sample size no multivariate
logistic regression analysis was performed. Effect sizes
were presented as odds ratios (OR) with their correspond-
ing 95% confidence intervals (95% CI). A risk score of 1 to
3 points was assigned to potential risk factors based on
their log odds ratios: ≤ 0.44 = 1 point; 0.45–0.94 = 2 points;
≥ 0.95 = 3 points.
Literature review on risk factors
A small dataset will not identify all potential risk factors
and a model can benefit from the information of previ-
ous studies. Therefore, a literature review was performed
[25, 26]. Additional risk factors from this review were
incorporated into the model when they are easily obtain-
able in tertiary and primary care. Large cohort studies
were retrieved from the database Medline. Study popula-
tion, cases of QTc-prolongation, formula to correct for
heart rate, cut-off values of QTc-prolongation and the
statistically significant risk factors associated with QTc-
prolongation were evaluated. The level of evidence was
determined based on the level of significance in the
studies evaluated. Also, reviews on drug-induced QTc-
prolongation were included to select relevant risk fac-
tors [2, 6, 12]. A risk score of 1 or 2 points was
assigned to the additional risk factors based on the
level of evidence.
External validation
The validity of the model was assessed in an independ-
ent dataset from a general teaching hospital to evaluate
model performance and clinical usefulness. All ECGs
that were recorded in routine clinical practice of ambula-
tory and hospitalized patients using two or more QTc-
prolonging drugs between January 21st, 2013 and October
10th, 2016 were extracted from the hospital information
system EPIC (Madison, WI, USA) using SAP Crystal Re-
ports (Walldorf, Germany). All ECGs were standard
twelve-lead resting ECGs with automatically calculated
heart rates (RR), QT-intervals and QRS-complexes by the
MUSE Cardiology Information System. Firstly, for ECGs
with QRS-complexes > 120ms, the QT-intervals were cor-
rected using the following equation: QT adjusted =QT –
(QRS – 120). The QT-intervals were then corrected for
heart rate using the Bazett and Fridericia formula [24]. A
prolonged QTc-interval was defined as QTc > 450ms for
males and > 470ms for females identical to the develop-
ment cohort. Because arrhythmias are often associated
with a QTc > 500ms, we performed a post-hoc analysis in
which QTc-prolongation was defined as QTc > 500 ms
[6, 7]. ECGs with a QTc-interval > 700 ms or < 300 ms,
or a VR > 180 bpm or < 40 bpm were excluded. Each pa-
tient was only included once using the first ECG avail-
able. Of these patients, data on risk factors included in
the risk model were extracted such as age, sex, serum
potassium (mmol L− 1), eGFR based on the MDRD (mL
min− 1), cardiac comorbidities (based on Anatomical
Therapeutic Chemical Classication (ATC) C01),
hypertension (based on ATC C02, C03, C07 – C09),
diabetes mellitus (based on ATC A10) concomitant
medication such as loop diuretics (based on ATC
C03CA) and the use of QTc-prolonging drugs at time
of ECG recording [27].
The QTc-intervals > 450 ms in males and > 470 ms in
females, and as post-hoc analysis QTc-intervals > 500 ms
as measured by the ECG were taken as outcome mea-
sures, to which the performance of the model was com-
pared. The model’s potential clinical usefulness was
assessed by its’ ability to distinguish patients with and
without QTc-prolongation. The discriminative ability
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was quantified with receiver operating characteristics
(ROC)-analyses, also known as concordance statistic (C-
statistic). Cut-off points for the model were selected by
maximizing the difference between sensitivity and 1
minus specificity. The primary focus was maximizing the
sensitivity to identify low-risk patients, while keeping
specificity at an acceptable level. Therefore, a cut-off
value with a sensitivity of > 75% in order to increase the
specificity as much as possible is accepted. Specificity,
sensitivity, accuracy, the false omission rate and the You-
den’s index were calculated as these are the most rele-
vant parameters for assessing clinical usability. Data are
presented as mean with their standard deviation (SD)
and median with their interquartile range (IQR).
Results
Study population
In total, 107 patients were included in the develop-
ment dataset, and 1579 patients were included in the
validation dataset. The flowchart of inclusion is
shown in Fig. 1 and the patients characteristics in
Table 1. The median age of the validation cohort
was significantly higher than the median age of the
development cohort (77 to respectively 56 years old).
Identification of risk factors
Of the 107 patients (43% female, median (IQR) age
56 (23)( years) included, twenty-seven (25.2%) showed a
prolonged QTc-interval on the ECG during treatment with
two or more QTc-prolonging drugs. In none of these pa-
tients the QTc-interval was prolonged to more than 500
ms. The results of the univariate logistic regression ana-
lyses using the Bazett formula are presented in Table 2.
A history of arrhythmia (OR 3.52; 95% CI 1.03–12.07) and
hypertension (OR 3.44; 95% CI 1.36–8.86) were significantly
associated with QTc-prolongation. The use of loop diuretics
(OR 3.65; 95% CI 1.18–11.25) was also identified as a poten-
tial risk factor for QTc-prolongation when using the
Fig. 1 Flowchart of patient inclusion of the development cohort. Abbreviations: DDI, drug-drug interactions; RBBB/LBBB, right or left bundle
branch block
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Fridericia formula. Risk score points were assigned to the
potential risk factors based on their odds ratios (Table 3).
Review from literature on additional risk factors
The literature review included reviews and cohort stud-
ies with 8453 patients in total [2, 15, 28–33]. Of the
8453 patients, 1772 patients (21%) showed QTc-
prolongation assuming the studies were sufficiently pow-
ered to determine potential risk factors [15, 28–31]. In
most studies [15, 29, 30], hypokalemia was highly associ-
ated with QTc-prolongation with a significance level of
p < 0.001. Due to the level of significance and the num-
ber of studies, severe hypokalemia (≤ 2.5 mmol L− 1) was
allocated 2 points and moderate hypokalemia (2.6–3.4
mmol L− 1) was allocated 1 point in the model. Female
sex was associated with QTc-prolongation in three stud-
ies [15, 30, 31] with a significance level of p < 0.05, so 1
point was assigned to female sex [2, 32]. The comorbidi-
ties renal failure and diabetes mellitus showed limited
evidence in the studies with significance levels of p <
0.05 [30, 32]. For QTc-prolonging drugs eliminated pri-
marily by renal excretion, an impaired renal function
can cause accumulation and toxicity of the QTc-
prolonging drugs. Hemodialysis patients are also at in-
creased risk for QTc-prolongation due to electrolyte ab-
normalities [34]. In addition, long-term glycemic
variabilities in patients with diabetes mellitus, can induce
QTc-prolongation; both comorbidities were therefore
assigned 1 point in the model [35, 36]. The use of QTc-
prolonging drugs with a known risk of TdP was highly
associated with QTc-prolongation in several studies (p <
0.01) [2, 11, 15, 29, 30]. As the model focused on pa-
tients using two or more QTc-prolonging drugs with a
known risk of TdP, QTc-prolonging drugs with a known
risk of TdP were incorporated in the model with 1 point.
The QTc-prolonging drugs with a possible and condi-
tional risk of TdP were not found to be associated with
QTc-prolongation in multiple cohort studies, and were
therefore not taken into account. The final clinical risk
model, is presented in Table 4.
External validation
In total, 6361 ECGs of patients using two or more QTc-
prolonging drugs were extracted from the hospital infor-
mation system EPIC (Madison, WI, USA). The ECGs in-
cluded in the validation dataset belonged to 2514 unique
patients. Because perioperative patients and patients
admitted to the intensive care unit (ICU) were not in-
cluded in the development cohort, we excluded QT-DDI
alerts in the validation cohort with propofol as these
alerts concerned perioperative and ICU patients. Also,
2 ECGs were excluded because the heart rates were >
180 bpm.
Eventually, the validation cohort consisted of 3891
ECGs of 1579 unique patients. The mean QTc-interval
of the first ECG available was 453.7 ms. In total, 655
(41.5%) ECGs showed a prolonged QTc-interval defined
as > 450/470 ms (m/f). The mean ± SD risk score of pa-
tients with a QTc-interval > 450/470ms (m/f) was 7.4 ±
2.5; the mean ± SD risk score of patients with a normal
QTc-interval was 7.2 ± 2.5.
Table 1 Patient characteristics of the development and validation cohort





Age (years), median; IQR 56.0; 23.0 77.0; 17.0 < 0.001a
≤ 50, n (%) 38 (35.5) 94 (6.0) < 0.001b
51–75, n (%) 60 (56.1) 646 (40.9)
≥ 76, n (%) 9 (8.4) 839 (53.1)
Female, n (%) 46 (43.0) 731 (46.3) 0.507b
Comorbidities, n (%)
Cardiac comorbidities 17 (15.9) 664 (42.1) < 0.001b
Hypertension 30 (28.0) 1064 (67.4) < 0.001b
Diabetes Mellitus 13 (12.1) 357 (22.6) 0.011b
eGFR (MDRD) (≤ 50 ml min−1), n (%) 9 (8.4) 439 (27.8) < 0.001b
Hypokalemia (< 3.5 mmol L− 1), n (%) 5 (4.7) 158 (10.0) 0.023b
> 2 QTc-prolonging drugs c, n (%) 7 (6.5) 101 (6.4) 0.953b
Loop diuretics, n (%) 23 (21.5) 400 (25.3) 0.376b
Abbreviations: eGFR, estimated Glomerular Filtration Rate; IQR, Interquartile Range
a Independent t test
b Chi-square test
c QTc-prolonging drugs with a known risk of TdP [13]
Missing values: Development cohort: eGFR, n = 2; K+, n = 1; Validation cohort: eGFR, n = 311; K+, n = 266; Validation cohort: eGFR, n = 310; K+, n = 265
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Table 2 The association of several risk factors with QTc-prolongation in the development cohort (Bazett formula)





Age (in years) median; IQR 58.0; 14.0 54.5; 23.0 1.02 0.99–1.05
≤ 25, n (%) 1 (3.7) 4 (5.0) Ref. Ref.
26–50, n (%) 5 (18.5) 28 (35.0) 0.71 0.07–7.79
51–75, n (%) 17 (63.0) 43 (53.8) 1.58 0.17–15.19
≥ 76, n (%) 4 (14.8) 5 (6.3) 3.20 0.25–41.21
Female gender, n (%) 4 (14.8) 42 (52.5) 0.16 0.05–0.50*
Caucasian race, n (%) 26 (96.3) 74 (92.5) 2.11 0.24–18.35
BMI (kg m2–1) a, mean ± SD 25.7 ± 4.3 27.3 ± 5.3 0.93 0.85–1.03
Clinical departments, n (%)
Medical Units 14 (51.9) 69 (86.3) Ref. Ref.
Surgical Units 9 (33.3) 8 (10.0) 5.55 1.82–16.86*
Cardiac Units 4 (14.8) 3 (3.8) 6.57 1.32–32.66*
Comorbidities
Myocardial infarction 1 (3.7) 1 (1.3) 3.04 0.18–50.32
Heart failure 1 (3.7) 3 (3.8) 0.99 0.10–9.91
Arrhythmia 6 (22.2) 6 (7.5) 3.52 1.03–12.07*
Hypertension 12 (48.1) 17 (21.3) 3.44 1.36–8.68*
Diabetes Mellitus 5 (18.5) 8 (10.0) 2.05 0.61–6.89
COPD/Asthma 1 (3.7) 11 (13.8) 0.24 0.03–1.96
Hematological malignancies 12 (44.4) 55 (68.8) 0.36 0.15–0.89*
Hepatic dysfunction b, n (%)
Increased ASAT (> 170 / 150 U L− 1) – 3 (3.8) – –
Increased ALAT (> 220 / 160 U L− 1) – 1 (1.3) – –
Increased bilirubin (> 16 μmol L− 1) 2 (7.4) 16 (20.0) 0.33 0.07–1.55
eGFR ≤50 ml min− 1 (MDRD) c, n (%) 3 (11.1) 6 (7.5) 1.50 0.35–6.47
Electrolyte disturbances d, n (%)
Hyponatremia (< 136mmol L− 1) 2 (7.4) 19 (23.8) 0.25 0.06–1.17
Hypokalemia (< 3.5 mmol L− 1) 2 (7.4) 3 (3.8) 2.03 0.32–12.83
Hypocalcemia (< 2.2 mmol L− 1) 7 (25.9) 17 (21.3) 1.29 0.39–4.22
Hypomagnesemia (< 0.7 mmol L− 1) 4 (14.8) 10 (12.5) 1.33 0.34–5.29
Concomitant medication, median; IQR 8.0; 4.0 8.0; 4.0 1.02 0.86–1.20
Loop diuretics, n (%) 8 (29.6) 15 (18.8) 1.83 0.67–4.95
QTc-prolonging drugs e, n (%)
0 4 (14.8) 11 (13.8) Ref. Ref.
1 6 (22.2) 28 (35.0) 0.59 0.14–2.50
≥ 2 17 (63.0) 41 (51.3) 1.14 0.32–4.09
Abbreviations: Ref. reference value; eGFR, estimated glomular filtration rate; IQR, interquartile range; BMI, body mass index; SD, standard deviation; OR, odds ratio; 95%
CI, 95% confidence interval
* Statistically significant
a Missing values: BMI: no QTc, n = 1
b Missing values: ASAT/ASAT: QTc, n = 5; no QTc, n = 7; Bili: QTc, n = 4; no QTc, n = 9
c Missing values: eGFR: no QTc, n = 2
d Missing values: Na+/K+: no QTc, n = 1; Ca2+: QTc, n = 12; no QTc, n = 38; Mg2+: QTc, n = 14; no QTc, n = 40
e Other than the QTc-prolonging drugs with a known risk of TdP [13]
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The area under the ROC-curve (AUROC) was 0.54
(95% CI 0.51–0.56) as shown in Fig. 2. The performance
characteristics of the model are presented in Table 5.
The selected optimal cut-off value was 6; 26.3% of all pa-
tients scored < 6 points. This cut-off value led to a sensi-
tivity of 76.6% and a specificity of 28.5% to predict
patients with a QTc-interval > 450/470 ms (m/f). Fig-
ures 3 and 4 show the distribution of the risk scores in
the external validation.
Post hoc analysis
In total, 155 ECGs (9.8%) showed a QTc-interval ex-
ceeding 500 ms. The mean ± SD risk score of patients
with a QTc-interval > 500 ms was 7.9 ± 2.5; the mean ±
SD risk score of patients with a normal QTc-interval
was 7.2 ± 2.5. The area under the ROC-curve (AUROC)
was 0.59 (95% CI 0.54–0.63) as shown in Fig. 2. The cut-
off value of 6 led to a sensitivity of 83.9% and a specifi-
city of 27.5% to predict patients with a QTc-interval >
500 ms. Figures 3 and 4 show the distribution of the risk
scores in the external validation when QTc-prolongation
was defined as > 500ms.
Discussion
We have developed a tool which enables the identifica-
tion of patients with an increased risk of QTc-
prolongation when using two or more QTc-prolonging
drugs with a known risk of TdP. We chose to develop a
tool based on seven predictors, that could easily be im-
plemented in everyday practice. The model was exter-
nally validated using an independent dataset of a general
teaching hospital, showing the robustness of the model.
Implementing such a model in clinical practice might
enhance the identification of high-risk patients which
will support healthcare providers in selecting patients in
whom the risk of QTc-prolongation is such that therapy
adjustment and/or additional ECG monitoring is re-
quired. At the same time such a model might also iden-
tify patients at low risk for developing cardiac
arrhythmia, and in whom there is no need for monitor-
ing ECGs after drug initiation, but further improvement
of the tool is needed. However, it should be noted that
the tool is not designed to fully replace healthcare pro-
viders in handling QT drug-drug interactions.
The model, developed in a university medical center,
showed insufficient discrimination abilities (AUROC <
0.60) when applied to a dataset from a general teaching
hospital. In the development cohort, we used a cut-off
value of 450 ms in men and 470 ms in women for a pro-
longed QTc-interval using the Bazett formula. The
Bazett formula often overestimates the QTc-interval in
patients with sinus tachycardia [37]. In the development
cohort, 91.6% of the patients had heart rates within the
range of 60–100 bpm. Arrhythmias are often associated
with QTc-intervals exceeding 500 ms [1, 8, 38]. There-
fore, we performed a post hoc analysis to compare both
reference values. The AUROC curve was 0.54 (95% CI
0.51–0.56) for QTc > 450/470 ms, but increased when
Table 3 Risk scores assigned to potential risk factors based on their Log OR
Bazett formula Fridericia formula
Predictors Log OR Score OR (95% CI) Log OR Score OR (95% CI)
Age (in years)
≤ 25 Ref. Ref. Ref. Ref. Ref. Ref.
26–50 − 0.15 0 0.71 (0.07–7.79) – – –
51–75 0.20 1 1.58 (0.17–15.19) – – –
≥ 76 0.51 2 3.20 (0.25–41.21) – – –
Arrhythmia 0.55 2 3.52 (1.03–12.07) – – –
Hypertension 0.54 2 3.44 (1.36–8.68) 0.77 2 5.92 (1.92–28.27)
Loop diuretics – – – 0.56 2 3.65 (1.18–11.24)
Abbreviations: Ref, reference value; OR, odds ratio; 95% CI, 95% confidence interval









Diabetes Mellitus I and II 1
eGFR ≤50 mLmin− 1 (MDRD) 1
Potassium levels
≤ 2.5 mmol L− 1 2
2.6–3.4 mmol L− 1 1
Loop diuretics 2
QTc-prolonging drugs with a known risk of TdP a 1
a Classified according to the CredibleMeds® QT drug lists [13]
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QTc-prolongation was defined as QTc > 500 ms (0.59,
95% CI 0.54–0.63). We were aiming for high sensitivities
to generate low numbers of false negatives, in order to
not miss patients at high risk for TdP. The model was
more sensitive in identifying QTc-intervals exceeding
500 ms. The optimized cut-off value of 6 resulted in a sen-
sitivity of 76.6% for the prediction of QTc > 450/470ms
and 83.9% for the prediction of QTc > 500ms.. However,
the low specificity (27.5%) means that the model incor-
rectly labels patients at risk for QTc-prolongation. Never-
theless, we focused on optimizing sensitivity in order to
prevent missing patients at risk for QTc-prolongation by
accepting sub-optimal specificity values. As the current
guidelines generate alerts in all patients, the guidelines
lead to a specificity of zero, so even a specificity of 27.5%
is an improvement. A perfect prediction model is not feas-
ible because there is a wide variability in the QTc-interval
independent of risk factors. And also, the incidence of
QTc-intervals above 500ms is relatively low [8, 19, 39].
Nevertheless, the sensitivity and specificity value of 83.9
and 27.5% should be optimized before broad implementa-
tion in clinical practice can be recommended.
Ideally, the model should be developed and validated
with TdP as primary outcome. As linear correlation is
lacking, it is questionable whether a prolonged QTc-
interval is an adequate marker for predicting the risk of
TdP [40]. Unfortunately, it is nearly impossible to identify
cases of TdP, because ECGs are frequently not available to
ensure TdP actually occurred. Furthermore, even in high
risk populations the incidence of TdP is extremely low, so
exceptionally large patient populations are needed to
study TdP as primary endpoint. So a prolonged QTc-
interval is still the most validated and frequently used sur-
rogate marker in clinical practice [2, 41].
Fig. 2 ROC-curves (> 450/470ms and > 500 ms) of the risk model in the external validation
Table 5 Performance characteristics of the risk model in the external validation when using different cut-off values
Performance characteristics Cut-off-value ≥ 5 Cut-off value≥ 6 Cut-off value≥ 7
> 450/470ms > 500ms > 450/470ms > 500ms > 450/470ms > 500ms
Sensitivity (%) 86.3 91.0 76.6 83.9 63.8 69.0
Specificity (%) 16.3 15.9 28.5 27.5 40.4 39.5
False Omission Rate (%) 37.3 5.8 36.8 6.0 38.9 7.9
Accuracy (%) 0.45 0.23 0.48 0.33 0.50 0.42
Youden’s index (%) 2.6 6.9 5.1 11.3 4.2 8.5
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Fig. 3 Distribution of the risk scores in the external validation cohort
Fig. 4 Proportion of ECGs with QTc-prolongation (> 450/470ms and > 500ms) versus risk scores in the external validation
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Several studies have already introduced risk models for
predicting QTc-prolongation/TdP. Haugaa et al. devel-
oped the ‘pro-QTc’ risk score, however, the primary
endpoint in their study was mortality which is a different
endpoint than the primary endpoint used in this study
[38]. Tisdale et al. developed a risk score via a similar
approach, but included only patients admitted to cardiac
care units [15]. Consequently, generalizability to a gen-
eral population may be limited. Vandael et al. recently
developed an optimized RISQ-PATH score to detect
high-risk patients for developing QTc-prolongation [42].
However, when this model was applied to patients using
two or more QTc-prolonging drugs, the sensitivity of
the model was 94.5%, but the specificity of the model
was even lower than our model (22.1%). Moreover, the
RISQ-PATH score of Vandael et al. consists of too many
predictors which are frequently not available and, there-
fore, this tool cannot be used in clinical practice. In
addition, this tool needs to be implemented in the clin-
ical decision support system before it is applicable in pri-
mary care, which does not seem feasible with the
current electronic patient health records. We aimed to
develop a risk score to detect high-risk patients when
using two or more QTc-prolonging drugs which is easily
applicable in both primary and hospital care.
A major strength of this study is that we externally
validated the risk model in an independent dataset from
a general teaching hospital. External validations are able
to determine the generalizability of predicting models in
different settings [43].
Several limitations of our study need to be addressed.
First, the study was limited by a single-center design for
model development; however, patients were admitted to
all general nursing departments representing a general
hospital population. Second, the sample size was rela-
tively small which increased the risk of model overfit-
ting; a common problem in models derived from small
datasets. By validating the model in a large external data-
set and by adding predictors based on a review of litera-
ture, the risk of overfitting was minimized [25, 26]. In
the validation cohort, there might have been selection
bias as the prevalence of QTc-prolongation (41.5%) was
quite high compared to the overall prevalence found in
the literature review (21%). We retrospectively collected
these data, so presumably, ECGs were mainly recorded
in high-risk patients. Our model does not take into account
the QTc-interval at baseline. Given that the risk on QTc-
prolongation increases when a high baseline QTc-interval
is present, we chose to exclude this potential predictor be-
cause baseline ECGs are frequently not available in clinical
practice. Also, the small dataset precluded the inclusion of
too many predictors in the model. Third, the tool does not
take into account the variety of QT-DDIs as our aim was to
develop an easily obtainable model that can be used in
different healthcare settings. Because of the different
pharmacological pathways of the QTc-prolonging drugs via
inhibition of the hERG channels or Cytochrome P450 en-
zymes, stratification of QT-DDIs is extremely complex and
larger studies need to be conducted for each QT-DDI
separately [44, 45].
The performance characteristics of the model were
not perfect. Also after performing a post-hoc analysis,
the discrimination ability of the model remained limited.
This can be explained by the discrepancies between the
development and validation cohort. First, the validation
dataset included patients from all departments including
ICU patients, whereas the development dataset only in-
cluded patients from medical wards. Unfortunately, we
could not exclude these patients in the validation data-
set, because it was unknown to which department pa-
tients had been admitted. Therefore, we decided to
exclude patients using propofol in order to exclude peri-
operative and ICU patients as much as possible. Also,
patients with ICDs or ECG abnormalities were not ex-
cluded in the validation cohort because these data could
not be extracted. Therefore, we excluded ECGs with de-
viant heart rates and QTc-intervals. We did correct the
QT-interval for wide QRS-complexes to limit ECG ex-
clusions. Second, the QTc-intervals of the development
cohort were manually measured, while the QTc-intervals
of the validation cohort were automatically calculated by
the MUSE Cardiology Information System. But most im-
portantly, the retrospective design of the external valid-
ation where only patients in whom an ECG was
recorded during use of the QTc-prolonging drugs were
included, may have led to selection bias. ECGs are more
likely to be recorded in vulnerable patients. According
to the high prevalence of comorbidities in the validation
cohort, this was probably the case. But even in high
risk populations, QTc-prolongation is not always
present resulting in false positives. Also, ECGs are
more likely to be recorded in patients with underlying
cardiac diseases or with suspected QTc-prolongation
even if they only have a few risk factors, resulting in
false negatives. Our preliminary results must therefore
be confirmed in large studies where this selections
bias is not present. The usability of the tool must be
evaluated in a clinical setting. For future perspectives,
this tool must be further studied to assess its effect
when it is integrated in an electronic decision support
system before implementation can be recommended.
A clinical decision support system is extensively used
by pharmacists, as it is part of their job to read DDI
alerts. Ideally, the system will automatically calculate
a risk score for the individual patient and only gener-
ate alerts in high-risk patients resulting in more spe-
cific alerts. Such a study should be performed in large
patient groups with clinically relevant endpoints.
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Conclusion
To conclude, we developed and validated a tool to predict
patients at risk for QTc-prolongation when using two or
more QTc-prolonging drugs. The model is able to predict
patients at risk for QTc-prolongation (> 500ms) with a
sensitivity of 83.9% and specificity of 27.5% at an opti-
mized cut-off value of 6. This tool might contribute to
support the risk management of QT-DDIs in clinical prac-
tice, but further testing of the tool is needed in study co-
horts without any selection bias. Eventually, a clinical
decision support tool will support healthcare providers in
selecting patients in whom monitoring ECGs or switching
therapy can be withheld, without compromising patient
safety.
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